“With the more contagious delta variant now dominant in the U.S. despite the widespread availability of vaccines, the need for effective treatments is once again growing more urgent,” notes the author of today’s article in regards to the resurgent coronavirus crisis. And based on phase 2 clinical trial results, the biopharmaceutical company he discusses may have a convenient, effective treatment for COVID-19 that “could swiftly transform [it] from an under-the-radar biotech into a major winner for shareholders.” For more, CLICK HERE.
An Effective Oral Therapy For COVID-19 Could Make This Under-The-Radar Biopharma Company A Big Winner
- by Alex Clarke
